- Assessment of Cytokine Release Syndrome (CRS)
In recent years, the flourishing development of antibody drugs and immunotherapy has heightened the importance of evaluating Cytokine Release Syndrome (CRS). The mechanisms of action of these drugs may lead to abnormal regulation of cytokine release, causing serious side effects. Therefore, assessing whether drugs aberrantly modulate the release of cytokines, leading to adverse effects, has become a focal point in safety assessments during clinical trials. Monitoring changes in the concentrations of cytokines within the body is crucial in both preclinical and clinical trial stages. This ensures a cautious evaluation of drug dosage and secures medication safety.
- Biomarker Assessment
Biomarkers play a pivotal role in the process of new drug development, offering insights into disease progression and evaluating drug efficacy. During trials, it is essential to closely monitor the concentrations of biomarkers within the body to assess the interrelation between drug dosage and pharmacodynamics. This facilitates timely and appropriate adjustments to dosages and frequencies, promoting the clinical trial in a safer and more effective manner.
Methods for Cytokine Analysis in Biological Samples - Cytometric Bead Array (CBA):
Compared to traditional ELISA, which analyzes one protein at a time, Cytometric Bead Array (CBA) is a more time-efficient, cost-effective, and specimen-saving analytical method. It enables the simultaneous quantitative analysis of approximately 30 cytokines using a small amount of specimen. The flexibility to combine different sets of cytokines allows for corresponding reference indicator combinations for various disease models, such as common inflammatory cytokines: IFN-γ, TNF-α, IL-1β, IL-2, and IL-6.
Services We Provide:
- Analysis method testing and qualification
- Biological sample analysis
- Analysis data reporting